Additional file 2: Figure S1. of AnnoLnc: a web server for systematically annotating novel human lncRNAs

The empirical NULL distribution of interaction scores generated by random shuffling (calculated by lncPro). The red line is for the cutoff p value (0.01). (DOCX 63 kb

Additional file 1: Table S1a. of AnnoLnc: a web server for systematically annotating novel human lncRNAs

The annotation result of “trancriptional regulation” of IncRNA H19. Table S1b. The annotation result of “miRNA interaction” of IncRNA H19. Table S2. The annotation result of “trait association” of IncRNA CCAT2. Table S3. RNA-Seq datasets of normal samples. Table S4. RNA-Seq datasets of cancer samples. Table S5. ChIP-Seq datasets. Table S6. miRNA families to run targetScan prediction. Table S7. CLIP Seq datasets of AGO. Table S8. CLIP-Seq datasets of RNA binding protein. (XLS 190 kb

Discovery of N‑Substituted Oseltamivir Derivatives as Potent and Selective Inhibitors of H5N1 Influenza Neuraminidase

To discover group-1-specific neuraminidase (NA) inhibitors that are especially involved in combating the H5N1 virus, two series of oseltamivir derivatives were designed and synthesized by targeting the 150-cavity. Among these, compound <b>20l</b> was the most potent N1-selective inhibitor, with IC₅₀ values of 0.0019, 0.0038, and 0.0067 μM against NAs from three H5N1 viruses. These values are better than those of oseltamivir carboxylate. Compound <b>32</b> was another potent N1-selective inhibitor that exhibited a 12-fold increase in activity against the H274Y mutant relative to oseltamivir carboxylate. Molecular docking studies revealed that the 150-cavity was an auxiliary binding site that may contribute to the high selectivity of these compounds. The present work is a significant breakthrough in the discovery of potent group-1-specific neuraminidase inhibitors, which may be further investigated for the treatment of infection by the H5N1 virus